title: Asymptomatic QTc prolongation during coadministration of aripiprazole and haloperidol.
authors: Roberto
authors: R
authors: Leo
authors: Cinzia
authors: C
authors: Razzini
authors: Giorgio
authors: G
authors: Di Lorenzo
authors: Francesco
authors: F
authors: Bianchi
authors: Manfredi
authors: M
authors: Tesauro
authors: Marco
authors: M
authors: Zanasi
authors: Alberto
authors: A
authors: Siracusano
authors: Francesco
authors: F
authors: Romeo
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D000068180:Aripiprazole; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D005260:Female; D006220:Haloperidol / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D006329:Heart Conduction System / Q000187:drug effects* / Q000503:physiopathology; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000503:physiopathology; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D015363:Quinolones / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology
chemical_list: D014150:Antipsychotic Agents; D010879:Piperazines; D015363:Quinolones; D000068180:Aripiprazole; D003577:Cytochrome P-450 Enzyme System; D006220:Haloperidol